回复高晓帅、陈果和魏鑫致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔法埃伊等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》2021年；79卷：783 - 92页 - Suppr | 超能文献

相似文献

1

Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.回复高晓帅、陈果和魏鑫致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔法埃伊等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》2021年；79卷：783 - 92页

Eur Urol. 2021 Dec;80(6):e145-e146. doi: 10.1016/j.eururo.2021.09.013. Epub 2021 Sep 25.

2

Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复约翰娜·诺埃尔、奥利维耶·于利亚尔和弗朗索瓦·戈德瓦塞尔致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人的《程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析》。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006。免疫检查点抑制剂的临床活性：宿主是答案吗？

Eur Urol. 2021 Apr;79(4):e113-e114. doi: 10.1016/j.eururo.2021.01.012. Epub 2021 Jan 21.

3

Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.回复：森庆一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔法埃伊等。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》2021年；79：783 - 92。

Eur Urol. 2021 Dec;80(6):e143-e144. doi: 10.1016/j.eururo.2021.09.012. Epub 2021 Sep 27.

4

Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复：森庆一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006：免疫检查点抑制剂的临床活性：宿主是答案吗？

Eur Urol. 2021 Apr;79(4):e112. doi: 10.1016/j.eururo.2021.01.013. Epub 2021 Jan 29.

5

Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.回复尼米什·辛格拉和维塔利·马尔古利斯致编辑的信，信中涉及：杰拉尔丁·皮尼奥、安托万·蒂埃里 - 维勒明、约亨·瓦尔兹等人。转移性肾细胞癌对免疫检查点抑制剂完全缓解后的肾切除术：一项新的手术挑战？《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2019.12.018。肾癌的下一个手术前沿：免疫检查点抑制后的肾切除术：免疫治疗后的肾切除术：治疗暴露时间可能起决定性作用。

Eur Urol. 2020 Aug;78(2):e81-e82. doi: 10.1016/j.eururo.2020.04.052. Epub 2020 May 7.

6

Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.回复：齐亚德·巴库尼、塔拉勒·埃尔·扎里夫、沙恩·杜达尼等人。免疫检查点抑制剂或靶向治疗的转移性肾细胞癌的 upfront 减瘤性肾切除术：来自国际转移性肾细胞癌数据库联盟的一项观察性研究。《欧洲泌尿外科杂志》2023 年；83 卷：145 - 151 页。

Eur Urol. 2023 Sep;84(3):e75. doi: 10.1016/j.eururo.2023.04.040. Epub 2023 Jun 1.

7

Reply to Daniel D. Shapiro, Jose A. Karam, Viraj A. Master, et al.'s Letter to the Editor re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.对丹尼尔·D·夏皮罗、何塞·A·卡拉姆、维拉杰·A·马斯特等人致编辑信的回复，信的主题为：韦斯利·叶、阿里雷扎·戈雷菲、托马斯·杰拉尔德等人。免疫检查点抑制剂治疗后肾切除术的围手术期并发症和肿瘤学结局：一项多中心合作研究。《欧洲泌尿外科肿瘤学》。《欧洲泌尿外科》。肿瘤学。2023年；604 - 610页。

Eur Urol Oncol. 2023 Dec;6(6):637. doi: 10.1016/j.euo.2023.05.010. Epub 2023 Jun 12.

8

Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.回复：杰拉尔丁·皮尼奥、安托万·蒂埃里 - 维勒明、约亨·瓦尔兹等。转移性肾细胞癌对免疫检查点抑制剂完全缓解后的肾切除术：一项新的外科挑战？《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2019.12.018：肾癌的下一个外科前沿：免疫检查点抑制后的肾切除术

Eur Urol. 2020 Aug;78(2):e79-e80. doi: 10.1016/j.eururo.2020.04.025. Epub 2020 Apr 30.

9

Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.对E. 贾森·阿贝尔致编辑的信的回复，主题为：洛伦佐·马尔科尼、赛义德·达贝斯塔尼、托马斯·B·林等人。经皮肾肿瘤活检诊断准确性的系统评价和Meta分析。《欧洲泌尿外科杂志》2016年；69卷：660 - 73页。

Eur Urol. 2016 Jun;69(6):e119-20. doi: 10.1016/j.eururo.2015.12.043. Epub 2016 Jan 14.

10

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.对阿里雷扎·戈雷菲和胡曼·贾拉达特致编辑的信的回复：关于丹尼尔·D·夏皮罗、何塞·A·卡拉姆、洛根·曾普等人的《免疫检查点抑制剂治疗后减瘤性肾切除术安全且有助于无治疗间期》。《欧洲泌尿外科开放科学》2023年；50:43 - 6。

Eur Urol. 2023 Aug;84(2):e55-e56. doi: 10.1016/j.eururo.2023.04.023. Epub 2023 May 5.